HOME >> MEDICINE >> NEWS
Depression caused by common treatment for hepatitis C may affect outcome

ATLANTAAn article appearing in the January 2005 issue of Brain, Behavior and Immunity suggests that developing depression while on interferon-alpha plus ribavirin may impact how well the medications work.

In a study conducted in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, Charles L. Raison, MD, Andrew Miller, MD, and colleagues, observed that patients who develop depressive symptoms during interferon-alpha plus ribavirin therapy were significantly less likely to have cleared the hepatitis C virus from their blood following six months of treatment.

"Hepatitis C infection affects three to five million Americans, and is the leading cause of liver transplantation," said Dr. Raison. "With advances in treatment, 40-50 percent of patients can be cleared of the virus. Unfortunately, however, the current treatment for hepatitis C interferon-alpha plus ribavirin produces a high rate of psychiatric side effects that have long been recognized as impediments to successful antiviral therapy. In the past we primarily worried that depression interfered with quality of life, or would cause patients to stop taking the medicine. These new data suggest that even if patients stay on treatment, they are less likely to have a good outcome if they develop depression."

The study examined 103 participants who received pegylated interferon-alpha-2b plus ribavirin (PEG IFN/ribavirin). All participants were psychiatrically evaluated prior to initiation of the medication and at 4, 8, 12 and 24 weeks of PEG IFN/ribavirin treatment.

Only 34% of the patients who had a significant increase in depression cleared the hepatitis C virus from their blood at 24 weeks, as compared to 59%-69% of patients with milder increases in depression. The effect of depression on viral clearance persisted even after adjusting for factors known to affect treatment outcome, such as viral genotype, or whether medications had to
'"/>

Contact: Kathi Baker
kobaker@emory.edu
404-727-9371
Emory University Health Sciences Center
14-Jan-2005


Page: 1 2

Related medicine news :

1. Depression linked to insomnia in HIV patients
2. Depression may explain higher risk of heart attack associated with antidepressants
3. Depression predicts heart rhythm abnormalities in heart attack patients
4. Depression tied to higher risk of heart disease death
5. Depression predicts mortality in women with heart disease
6. Depression can lead to back pain
7. Depression on College Campuses conference
8. Depression may be a risk factor for heart disease, death in older women
9. Depression, other psychiatric illnesses common following traumatic brain injury
10. Depression, trauma stress linked to physical complaints
11. Depression doubles risk of death after bypass surgery

Post Your Comments:
(Date:8/1/2015)... ... ... and Lita Hart, icons of the network marketing industry and founders of the Healthy ... Movement of EvolvHealth. In what has been a long-term relationship between the companies for ... of purpose together to change the course of the network marketing industry. , “This ...
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, which ... Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the ... message including ones already sent. , While text messaging has more features than it ...
(Date:7/31/2015)... ... ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened a ... July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and Latin ... Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department of ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... introduced its new store run by GoodThreads. The store can be accessed by ... and designs, many of which are customizable. The best part: whenever a product ...
(Date:7/31/2015)... Meadows, IL (PRWEB) , ... July 31, 2015 ... ... ways to communicate. Rally Insurance Group, Inc. has re-branded their social media profiles ... provides a personal way for consumers to communicate, find information, share insights and ...
Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2
(Date:7/31/2015)... LAKE, N.J. and SAN DIEGO ... today that its parent company Eisai Co., Ltd. (Headquarters: ... Haruo Naito , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... CEO: Dr. Helen Torley , "NASDAQ: HALO") have ... mesylate (brand name: Halaven ® , "eribulin") in combination ...
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
Cached News: